Ferring commits further to Antares devices:
This article was originally published in Clinica
Executive Summary
Ferring Pharmaceuticals of Denmark has expanded its partnership with Antares Pharma covering the latter's needle-free delivery devices. Ferring already markets the Exton, Pennsylvania firm's Medi-Jector Vision device for use with the growth hormone product, Zomacton. It now plans to access newer versions of Antares' devices at a cost of E1.5m ($1.6m). The currently marketed product, branded Zomajet 2 Vision, is a reusable spring-loaded device that loads the drug from a vial and delivers it as a fine liquid stream.